ID

34573

Description

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02240238

Link

https://clinicaltrials.gov/show/NCT02240238

Keywords

  1. 1/19/19 1/19/19 -
  2. 9/28/20 9/28/20 -
  3. 10/1/20 10/1/20 -
Copyright Holder

see on clinicaltrials.gov

Uploaded on

January 19, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Solid Tumors NCT02240238

Eligibility Solid Tumors NCT02240238

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
(part 1 only) have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy.
Description

ID.1

Data type

boolean

(part 2 only) have histologically or cytologically confirmed diagnosis of stage iiib or iv nsclc and have received 1 or 2 lines of prior chemotherapy or targeted therapy for stage iiib or iv nsclc (second- or third-line).
Description

ID.2

Data type

boolean

have measurable disease per response evaluation criteria in solid tumors (recist) version 1.1.
Description

ID.3

Data type

boolean

eastern cooperative oncology group (ecog) performance status of 0 to 1
Description

ID.4

Data type

boolean

have adequate bone marrow reserve, liver function, and renal function
Description

ID.5

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
have received prior platinum therapy in the past 3 months
Description

ID.6

Data type

boolean

have received prior cisplatin and gemcitabine concomitantly within the last 6 months or are refractory to cisplatin and gemcitabine.
Description

ID.7

Data type

boolean

unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment
Description

ID.8

Data type

boolean

pregnant or breast feeding
Description

ID.9

Data type

boolean

Similar models

Eligibility Solid Tumors NCT02240238

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
(part 1 only) have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy.
boolean
ID.2
Item
(part 2 only) have histologically or cytologically confirmed diagnosis of stage iiib or iv nsclc and have received 1 or 2 lines of prior chemotherapy or targeted therapy for stage iiib or iv nsclc (second- or third-line).
boolean
ID.3
Item
have measurable disease per response evaluation criteria in solid tumors (recist) version 1.1.
boolean
ID.4
Item
eastern cooperative oncology group (ecog) performance status of 0 to 1
boolean
ID.5
Item
have adequate bone marrow reserve, liver function, and renal function
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
have received prior platinum therapy in the past 3 months
boolean
ID.7
Item
have received prior cisplatin and gemcitabine concomitantly within the last 6 months or are refractory to cisplatin and gemcitabine.
boolean
ID.8
Item
unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment
boolean
ID.9
Item
pregnant or breast feeding
boolean

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial